Bayer starts clinical trial with novel compound against MTAP-deficient tumours

Bayer holds the exclusive development, manufacturing and commercialisation rights and has already enrolled the first patient in a phase I clinical trial. The product is based on an MTA-dependent mechanism of action that makes it possible to specifically attack tumour cells and spare healthy tissue. This could open up new therapeutic options, particularly for difficult-to-treat cancers such as glioblastoma or pancreatic cancer. In preclinical studies, the PRMT5 inhibitor not only demonstrated high selectivity, but also the ability to cross the blood-brain barrier. This means that brain metastases or primary brain tumours could also be treated. The development of BAY 3713372 strengthens Bayer's growing portfolio in early-stage precision oncology research. The financial details of the agreement were not disclosed.